Agilent Technologies extended a collaboration with Belgium's University of Leuven to focus on detecting genetic abnormalities in cell-free DNA and embryo biopsies. The two parties will also investigate solutions for pre-implantation genetic testing and believe that a commercial solution for PGT analysis could be available as early as this year.